Understanding the Mechanisms of DC Licensing in CD8 T Cell Priming
了解 CD8 T 细胞启动中 DC 许可的机制
基本信息
- 批准号:10630938
- 负责人:
- 金额:$ 46.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:Antigen PresentationAntigen-Presenting CellsAntigensAntitumor ResponseCD4 Positive T LymphocytesCD40 LigandCD8-Positive T-LymphocytesCD8B1 geneCardiolipinsCell CommunicationCellsCross PresentationDataDendritic CellsDevelopmentEnhancersExclusionGene DeletionGenesHelper-Inducer T-LymphocyteIndividualKnowledgeLicensingLigandsLipidsMethodsModelingMusNaturePathway interactionsProcessPublishingRoleSignal InductionSignal TransductionSourceT cell responseT-Cell ReceptorT-LymphocyteTNFRSF5 geneTNFSF5 geneTestingTimeTumor ImmunityTumor PromotionTumor-DerivedVirusWorkarmcell typein vivoneoantigensnew therapeutic targetnovelpathogenprogramsresponsetranscription factortransgene expressiontumorγδ T cells
项目摘要
ABSTRACT
Effective responses to viruses, intracellular pathogens and tumors rely on the successful expansion and arming of cytolytic CD8 T cells from a naïve and quiescent T cell repertoire. This process, called CD8 T cell priming, is dependent on a specialized antigen-presenting cell known as conventional dendritic cells (cDCs). Recent studies from our lab have shown that a specific type of dendritic cells, called cDC1, is responsible for CD8
T cell priming and depends on the transcription factor Batf3 for development. In the process of priming CD8 T
cells, the cDC1 captures foreign antigens or tumor-specific neo-antigens, and presents these antigens on the
MHC-I molecule in order to stimulate the T cell receptor (TCR) of the CD8 T cell. In the absence of cDC1, such
as in Batf3-deficient mice, CD8 T cells are not activated against viruses or tumors. In addition, however, full
activation of CD8 T cell requires that cDC1 receive signals that program its ability to fully activate CD8 T cells.
This process is called `DC licensing', but is currently not fully characterized. Our recent work has shown that
current models for DC licensing are incomplete. Specifically, while we have confirmed the requirement for
CD40 signaling in response to CD40L provided by a helper cell, we have shown that the expected target of
CD40, CD70, does not explain the beneficial effect of DC licensing for tumor rejection. This result implies that
additional targets of CD40 are needed to understand DC licensing. Further, it has been thought that CD4 T
cells are the exclusive agent in the licensing process. However, these conclusions derived from older studies
and less precise methods. In contrast, we developed an Xcr1-Cre deletor strain to delete genes specifically
from cDC1, and found unexpected results, that CD4 T cells are not always critical for cDC1 licensing, suggesting that other cells expressing CD40L may be involved. Further, mechanism by which CD40 signaling induces
licensing of the cDC1 is unclear. Several mechanisms have been proposed, but our preliminary data excludes
the major proposed mechanism, those invoking CD70, as being critical for the effect of licensed cDC1 in priming CD8 T cells. Our proposal will first test (Aim 1) which Batf3-specific genes expressed in cDC1 are important
for cDC1 to support CD8 T cells responses. Second (Aim 2), we will determine identify the targets of CD40
signaling in cDC1 that are required for fully activating CD8 T cells. Finally, in Aim 3, we will test the role of cells
that we have identified as alternative sources of CD40 ligand, including iNKT cells and γδ T cells.
抽象的
对病毒、细胞内病原体和肿瘤的有效反应依赖于来自幼稚和静止 T 细胞库的溶细胞 CD8 T 细胞的成功扩增和武装。这个过程称为 CD8 T 细胞启动,依赖于一种称为传统树突细胞 (cDC) 的特殊抗原呈递细胞。我们实验室最近的研究表明,一种称为 cDC1 的特定类型的树突状细胞负责 CD8
T 细胞启动并依赖转录因子 Batf3 进行发育。在启动 CD8 T 的过程中
细胞中,cDC1捕获外来抗原或肿瘤特异性新抗原,并将这些抗原呈递到细胞上。
MHC-I 分子以刺激 CD8 T 细胞的 T 细胞受体 (TCR)。在没有 cDC1 的情况下,这样
与 Batf3 缺陷小鼠一样,CD8 T 细胞不会被激活来对抗病毒或肿瘤。然而除此之外,满
CD8 T 细胞的激活需要 cDC1 接收信号来编程其完全激活 CD8 T 细胞的能力。
该过程称为“DC 许可”,但目前尚未完全表征。我们最近的工作表明
当前的 DC 许可模型并不完整。具体来说,虽然我们已经确认了以下要求
CD40 信号响应辅助细胞提供的 CD40L,我们已经表明预期的目标
CD40、CD70并不能解释DC许可对肿瘤排斥的有益作用。这个结果意味着
需要 CD40 的其他目标来理解 DC 许可。此外,人们认为 CD4 T
cells是许可过程中的独家代理。然而,这些结论来自较早的研究
以及不太精确的方法。相比之下,我们开发了 Xcr1-Cre 删除菌株来特异性删除基因
并发现了意想不到的结果,即 CD4 T 细胞对于 cDC1 许可并不总是至关重要,这表明表达 CD40L 的其他细胞可能也参与其中。此外,CD40信号传导诱导的机制
CDC1 的许可情况尚不清楚。已经提出了几种机制,但我们的初步数据不包括
主要提出的机制,即调用 CD70 的机制,对于许可的 cDC1 在启动 CD8 T 细胞中的作用至关重要。我们的建议将首先测试(目标 1)cDC1 中表达的哪些 Batf3 特异性基因是重要的
cDC1 支持 CD8 T 细胞反应。第二(目标2),我们将确定CD40的靶标
充分激活 CD8 T 细胞所需的 cDC1 信号传导。最后,在目标3中,我们将测试细胞的作用
我们已确定 CD40 配体的替代来源,包括 iNKT 细胞和 γδ T 细胞。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kenneth M Murphy其他文献
Competition for cytokines: Treg cells take all
细胞因子的竞争:调节性 T 细胞独占鳌头
- DOI:
10.1038/ni1207-1285 - 发表时间:
2007-12-01 - 期刊:
- 影响因子:27.600
- 作者:
Alexander Scheffold;Kenneth M Murphy;Thomas Höfer - 通讯作者:
Thomas Höfer
Recent progress in type 1 classical dendritic cell cross-presentation - cytosolic, vacuolar, or both?
- DOI:
10.1016/j.coi.2023.102350 - 发表时间:
2023-08-01 - 期刊:
- 影响因子:
- 作者:
Ray A Ohara;Kenneth M Murphy - 通讯作者:
Kenneth M Murphy
Kenneth M Murphy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kenneth M Murphy', 18)}}的其他基金
Transcriptional basis of embryonic macrophage development
胚胎巨噬细胞发育的转录基础
- 批准号:
10531441 - 财政年份:2022
- 资助金额:
$ 46.68万 - 项目类别:
Transcriptional basis of embryonic macrophage development
胚胎巨噬细胞发育的转录基础
- 批准号:
10654858 - 财政年份:2022
- 资助金额:
$ 46.68万 - 项目类别:
Understanding the Mechanisms of DC Licensing in CD8 T Cell Priming
了解 CD8 T 细胞启动中 DC 许可的机制
- 批准号:
10211694 - 财政年份:2021
- 资助金额:
$ 46.68万 - 项目类别:
Understanding the Mechanisms of DC Licensing in CD8 T Cell Priming
了解 CD8 T 细胞启动中 DC 许可的机制
- 批准号:
10411993 - 财政年份:2021
- 资助金额:
$ 46.68万 - 项目类别:
Mechanism of c-MYC repression by IRF8 in myeloid lineages
IRF8 在骨髓谱系中抑制 c-MYC 的机制
- 批准号:
10379675 - 财政年份:2021
- 资助金额:
$ 46.68万 - 项目类别:
Mechanism of c-MYC repression by IRF8 in myeloid lineages
IRF8 在骨髓谱系中抑制 c-MYC 的机制
- 批准号:
10493389 - 财政年份:2021
- 资助金额:
$ 46.68万 - 项目类别:
Function of Wdfy4 in cross-presentation and immunity
Wdfy4在交叉呈递和免疫中的功能
- 批准号:
10203752 - 财政年份:2019
- 资助金额:
$ 46.68万 - 项目类别:
Function of Wdfy4 in cross-presentation and immunity
Wdfy4在交叉呈递和免疫中的功能
- 批准号:
10430144 - 财政年份:2019
- 资助金额:
$ 46.68万 - 项目类别:
相似海外基金
Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
- 批准号:
10751133 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
- 批准号:
10696138 - 财政年份:2022
- 资助金额:
$ 46.68万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10663066 - 财政年份:2022
- 资助金额:
$ 46.68万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10537159 - 财政年份:2022
- 资助金额:
$ 46.68万 - 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
- 批准号:
21K08723 - 财政年份:2021
- 资助金额:
$ 46.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10156950 - 财政年份:2021
- 资助金额:
$ 46.68万 - 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
- 批准号:
10631854 - 财政年份:2021
- 资助金额:
$ 46.68万 - 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
- 批准号:
10153927 - 财政年份:2021
- 资助金额:
$ 46.68万 - 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10331830 - 财政年份:2021
- 资助金额:
$ 46.68万 - 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
- 批准号:
20K16294 - 财政年份:2020
- 资助金额:
$ 46.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists